Literature DB >> 10770726

Introduction to antifungal drugs.

W E Dismukes1.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10770726     DOI: 10.1086/313748

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  50 in total

1.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

3.  In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.

Authors:  Andreja Hasenoehrl; Tatjana Galic; Gabrijela Ergovic; Natasa Marsic; Mihael Skerlev; Joachim Mittendorf; Ulrich Geschke; Axel Schmidt; Wolfgang Schoenfeld
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  SPK-843 (Aparts/Kaken).

Authors:  Noer Kasanah; Mark T Hamann
Journal:  Curr Opin Investig Drugs       Date:  2005-08

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

Authors:  Annie Philip; Zekaver Odabasi; Jose Rodriguez; Victor L Paetznick; Enuo Chen; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 7.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

8.  Antagonistic changes in sensitivity to antifungal drugs by mutations of an important ABC transporter gene in a fungal pathogen.

Authors:  Wenjun Guan; Huifeng Jiang; Xiaoxian Guo; Eugenio Mancera; Lin Xu; Yudong Li; Lars Steinmetz; Yongquan Li; Zhenglong Gu
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

9.  Anidulafungin.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants.

Authors:  Ga Won Jeon; Soo Hyun Koo; Jang Hoon Lee; Jong Hee Hwang; Sung Shin Kim; Eun Kyung Lee; Wook Chang; Yun Sil Chang; Won Soon Park
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.